Common misconceptions about PhenoAge
PhenoAge is a biological age estimator derived from clinical biomarkers. This page addresses common misconceptions and summarises research on its measurement, variability, and application in study populations.
PhenoAge is a biological age estimator, also referred to as a phenotypic age clock, that uses a panel of routine clinical biomarkers to calculate an individual's biological age. It belongs to the class of aging clocks, which are tools designed to assess the pace of aging and calculate age acceleration—the difference between chronological and biological age [1]. Unlike epigenetic clocks that rely on DNA methylation patterns, PhenoAge is based on phenotypic markers. The evidence block does not provide a sequence, formula, or molecular weight for PhenoAge, as it is a statistical construct rather than a discrete molecule.
The research on PhenoAge centres on the pathways and mechanisms of aging, including metabolic and cellular processes that are captured by the biomarker panel. The specific pathway or receptor family is not detailed in the evidence provided.
Research Studies
PhenoAge and seasonal variation in biological age
A clinical trial is investigating how seasonal variations influence biological age, including measures such as PhenoAge. The study aims to provide insights on how seasonal changes affect biological age and to enhance the design and analysis of long-term lifestyle interventions targeting biological clocks [1]. This research is conducted in adult populations and highlights that biological age estimates may fluctuate with environmental factors.
PhenoAge and calcium alpha-ketoglutarate supplementation
A randomized, double-blind, placebo-controlled clinical trial is evaluating the effects of calcium alpha-ketoglutarate (CaAKG) supplementation on biological aging and age-related health indicators in middle-aged and older adults. Alpha-ketoglutarate (AKG) is a key intermediate in the Krebs cycle and has been investigated for its potential role in modulating aging-related metabolic and cellular pathways. Due to poor oral bioavailability of free AKG, the stabilized form CaAKG is used to enhance absorption. The trial aims to assess systematic effects on biological aging, which may include PhenoAge as an outcome measure [2].
PhenoAge and genetic susceptibility in Asian populations
A genome-wide association study (GWAS) was conducted on epigenetic age acceleration (EAA) using multiple epigenetic clocks in a Korean population. The study identified Asian-specific genetic susceptibility for epigenetic age acceleration [3]. While this research focuses on epigenetic clocks, it underscores the importance of population-specific factors in aging research, which may also apply to phenotypic clocks like PhenoAge.
PhenoAge and age acceleration calculation
Biological age clocks, including PhenoAge, are used to calculate age acceleration, defined as the difference between chronological and biological age [1]. This metric is valuable for assessing the pace of aging in individuals and populations. The evidence indicates that such calculations are emerging as tools for evaluating interventions targeting biological clocks.
PhenoAge in long-term lifestyle interventions
Research on seasonal variations in biological age is designed to enhance the design and analysis of long-term lifestyle interventions targeting biological clocks [1]. This suggests that PhenoAge may be used as an outcome measure in studies aiming to modify aging trajectories through lifestyle changes. The specific effects observed in these interventions are not detailed in the evidence.
PhenoAge and metabolic pathways
Alpha-ketoglutarate, a key intermediate in the Krebs cycle, has been investigated for its potential role in modulating aging-related metabolic and cellular pathways [2]. PhenoAge, as a phenotypic clock, may reflect changes in these pathways through its biomarker components. However, direct evidence linking PhenoAge to AKG supplementation is not provided in the evidence block.
PhenoAge and population-level assessment
At the population level, there is currently a lack of systematic assessment studies on the effects of CaAKG supplementation on biological aging [2]. This gap highlights the need for further research to understand how interventions affect PhenoAge and other biological age measures across diverse populations.
PhenoAge and ethnic differences
A GWAS of epigenetic age acceleration in a Korean population identified Asian-specific genetic susceptibility [3]. While this study focused on epigenetic clocks, it raises the possibility that phenotypic clocks like PhenoAge may also exhibit population-specific variations. The evidence does not directly address PhenoAge in this context.
PhenoAge and clinical trial design
Clinical trials are evaluating interventions such as CaAKG on biological aging, with PhenoAge potentially serving as an outcome measure [2]. The design of these trials, including randomization and placebo control, aims to provide rigorous evidence on the efficacy of such interventions. The results of these trials are not yet available in the evidence block.
If you are reading this for personal health reasons
The material discussed here is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.